Diamyd Medical appoints new CEO
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that the Company’s Board of Directors has appointed Ulf Hannelius, PhD, MBA, to new CEO.Ulf Hannelius (40), PhD in molecular biology from Karolinska Institute and with an MBA from Stockholm School of Economics has been appointed to, and today assumes, the position as CEO of Diamyd Medical. ”Ulf Hannelius has since November 2015 been working side by side with Diamyd Medical’s interim CEO Anders Essen-Möller”, says Erik Nerpin, Chairman of the Board of the Company. “It is satisfying that we have succeeded to